TaiGen Biopharmaceuticals Holdings Limited (4157.TWO)
TWD 9.68
(-9.95%)
TWD 9.68
(-9.95%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -299.96 Million TWD | -46.58% |
| 2022 | -204.63 Million TWD | 34.3% |
| 2021 | -311.47 Million TWD | -612.25% |
| 2020 | -43.73 Million TWD | 37.58% |
| 2019 | -70.06 Million TWD | 52.69% |
| 2018 | -148.1 Million TWD | 19.21% |
| 2017 | -183.31 Million TWD | -15.71% |
| 2016 | -158.42 Million TWD | -43.49% |
| 2015 | -110.41 Million TWD | -10.87% |
| 2014 | -99.58 Million TWD | 67.95% |
| 2013 | -310.74 Million TWD | 51.03% |
| 2012 | -634.55 Million TWD | -28.79% |
| 2011 | -492.72 Million TWD | 43.17% |
| 2010 | -867.03 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -128.46 Million TWD | 15.18% |
| 2024 Q1 | -151.45 Million TWD | 49.51% |
| 2023 Q3 | -10.77 Million TWD | 79.23% |
| 2023 Q4 | -299.96 Million TWD | -2683.93% |
| 2023 FY | -299.96 Million TWD | -46.58% |
| 2023 Q1 | -217.37 Million TWD | -6.22% |
| 2023 Q2 | -51.88 Million TWD | 76.13% |
| 2022 Q1 | -563.68 Million TWD | -80.97% |
| 2022 FY | -204.63 Million TWD | 34.3% |
| 2022 Q4 | -204.63 Million TWD | 0.27% |
| 2022 Q2 | -570.16 Million TWD | -1.15% |
| 2022 Q3 | -205.18 Million TWD | 64.01% |
| 2021 Q3 | -472.11 Million TWD | -252.85% |
| 2021 Q4 | -311.47 Million TWD | 34.03% |
| 2021 Q1 | -42.31 Million TWD | 3.23% |
| 2021 Q2 | -133.8 Million TWD | -216.18% |
| 2021 FY | -311.47 Million TWD | -612.25% |
| 2020 Q2 | -76.99 Million TWD | 6.94% |
| 2020 Q1 | -82.73 Million TWD | -18.08% |
| 2020 Q3 | -80.28 Million TWD | -4.28% |
| 2020 FY | -43.73 Million TWD | 37.58% |
| 2020 Q4 | -43.73 Million TWD | 45.53% |
| 2019 Q1 | -83.86 Million TWD | 43.38% |
| 2019 Q4 | -70.06 Million TWD | 16.13% |
| 2019 FY | -70.06 Million TWD | 52.69% |
| 2019 Q3 | -83.54 Million TWD | 42.32% |
| 2019 Q2 | -144.83 Million TWD | -72.7% |
| 2018 Q4 | -148.1 Million TWD | 54.89% |
| 2018 FY | -148.1 Million TWD | 19.21% |
| 2018 Q3 | -328.3 Million TWD | 50.73% |
| 2018 Q2 | -666.35 Million TWD | -671.71% |
| 2018 Q1 | -86.34 Million TWD | 52.9% |
| 2017 FY | -183.31 Million TWD | -15.71% |
| 2017 Q2 | -774.64 Million TWD | -4.8% |
| 2017 Q3 | -766 Million TWD | 1.11% |
| 2017 Q4 | -183.31 Million TWD | 76.07% |
| 2017 Q1 | -739.15 Million TWD | -366.56% |
| 2016 FY | -158.42 Million TWD | -43.49% |
| 2016 Q4 | -158.42 Million TWD | 1.39% |
| 2016 Q3 | -160.65 Million TWD | 74.46% |
| 2016 Q2 | -629 Million TWD | -7.93% |
| 2016 Q1 | -582.8 Million TWD | -427.86% |
| 2015 Q2 | -124.53 Million TWD | -11.06% |
| 2015 FY | -110.41 Million TWD | -10.87% |
| 2015 Q4 | -110.41 Million TWD | 75.3% |
| 2015 Q3 | -446.99 Million TWD | -258.93% |
| 2015 Q1 | -112.13 Million TWD | -12.6% |
| 2014 Q2 | -397.11 Million TWD | 39.17% |
| 2014 Q3 | -90.21 Million TWD | 77.28% |
| 2014 Q4 | -99.58 Million TWD | -10.39% |
| 2014 Q1 | -652.81 Million TWD | -110.08% |
| 2014 FY | -99.58 Million TWD | 67.95% |
| 2013 FY | -310.74 Million TWD | 51.03% |
| 2013 Q1 | 634.55 Million TWD | 200.0% |
| 2013 Q2 | -317.12 Million TWD | -149.98% |
| 2013 Q3 | -321.35 Million TWD | -1.33% |
| 2013 Q4 | -310.74 Million TWD | 3.3% |
| 2012 Q4 | -634.55 Million TWD | 0.0% |
| 2012 FY | -634.55 Million TWD | -28.79% |
| 2011 FY | -492.72 Million TWD | 43.17% |
| 2010 FY | -867.03 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Anti-Microbial Savior BioteQ Co., Ltd | -77.04 Million TWD | -289.346% |
| SYN-TECH Chem. & Pharm. Co., Ltd. | -264.16 Million TWD | -13.552% |
| Level Biotechnology Inc. | -453.9 Million TWD | 33.914% |
| Sagittarius Life Science Corp | -120.57 Million TWD | -148.792% |
| NeoCore Technology Co., Ltd. | -196.39 Million TWD | -52.736% |
| TaiMed Biologics Inc. | 499.84 Million TWD | 160.012% |
| GlycoNex Incorporation | -148.56 Million TWD | -101.908% |
| VBI | -25.31 Million TWD | -1084.895% |
| GeneReach Biotechnology Corp. | 40.26 Million TWD | 844.966% |
| Taiwan Advance Bio-Pharmaceutical Inc. | 137.99 Million TWD | 317.376% |
| SynCore Biotechnology Co.,Ltd | -262.58 Million TWD | -14.238% |
| Genomics BioSci & Tech. Co.,Ltd. | 30.57 Million TWD | 1080.993% |
| Visgeneer Inc. | 31.28 Million TWD | 1058.854% |
| Mycenax Biotech Inc. | 207 Million TWD | 244.906% |
| Sunmax Biotechnology Co., Ltd. | -680.6 Million TWD | 55.926% |
| G&E Herbal Biotechnology Co., Ltd. | -134.25 Million TWD | -123.437% |
| Neith Corporation | -150.31 Million TWD | -99.565% |
| Medigen Vaccine Biologics Corporation | 621.53 Million TWD | 148.262% |
| TaiwanJ Pharmaceuticals Co., Ltd. | -57.65 Million TWD | -420.254% |
| Enimmune corporation | -314.15 Million TWD | 4.517% |
| TaiRx, Inc. | -147.86 Million TWD | -102.861% |
| CHO Pharma, Inc. | -203.79 Million TWD | -47.193% |
| EirGenix Inc. | -4.58 Billion TWD | 93.462% |
| BioLASCO Taiwan Co., Ltd. | -84.76 Million TWD | -253.89% |
| Sunny Pharmtech Inc. | 120.87 Million TWD | 348.172% |
| Lin BioScience, Inc. | -3.21 Billion TWD | 90.679% |
| BioGend Therapeutics Co., Ltd. | -317.41 Million TWD | 5.497% |
| Feng Chi Biotech Corp. | -19.81 Million TWD | -1413.996% |
| Bio Preventive Medicine Corp. | 31.8 Million TWD | 1043.029% |
| Lukas Biomedical Inc. | 50.75 Million TWD | 691.012% |
| RBC Bioscience Corporation | 422.18 Million TWD | 171.051% |
| BiOptic Inc. | 12.59 Million TWD | 2482.211% |
| BRIM Biotechnology, Inc. | -944.4 Million TWD | 68.237% |
| Shine-On BioMedical Co.,Ltd. | -101.48 Million TWD | -195.576% |
| Great Novel Therapeutics Biotech & Medicals | -165.17 Million TWD | -81.605% |
| Syngen Biotech Co.,Ltd. | 314.87 Million TWD | 195.266% |
| Advagene Biopharma Co., Ltd. | -64.32 Million TWD | -366.361% |
| NaviFUS Corp. | -123.12 Million TWD | -143.621% |
| Gwo Xi Stem Cell Applied Technology Co. , Ltd | 74.05 Million TWD | 505.083% |
| Sinew Pharma Inc. | -160.34 Million TWD | -87.077% |
| Andros Pharmaceuticals Co.,Ltd | -241.89 Million TWD | -24.009% |
| Greenyn Biotechnology Co., Ltd | -337.37 Million TWD | 11.087% |
| Lumosa Therapeutics Co., Ltd. | -412.63 Million TWD | 27.305% |
| AP Biosciences Inc | -196.52 Million TWD | -52.634% |
| Medigen Biotechnology Corp. | 688.73 Million TWD | 143.553% |
| 3D Global Biotech Inc. | -11.43 Million TWD | -2522.786% |
| Pharmosa Biopharm Inc. | -829.69 Million TWD | 63.846% |
| Intech Biopharm Corporation | 1.35 Billion TWD | 122.1% |
| Oneness Biotech Co., Ltd. | -414.87 Million TWD | 27.697% |
| Eusol Biotech Co.,Ltd. | -209.33 Million TWD | -43.294% |
| TWi Biotechnology, Inc. | -143.86 Million TWD | -108.509% |
| Ever Supreme Bio Technology Co., Ltd | -330.54 Million TWD | 9.25% |
| TCI GENE Inc. | -689.25 Million TWD | 56.479% |
| MegaPro Biomedical Co., Ltd | -118.93 Million TWD | -152.205% |
| Senhwa Biosciences, Inc. | -1.3 Billion TWD | 77.088% |
| Taiwan Bio Therapeutics Co., Ltd | 20.48 Million TWD | 1564.473% |
| NatureWise Biotech & Medicals Corporation | -101.87 Million TWD | -194.462% |
| PharmaEngine, Inc. | -860.8 Million TWD | 65.153% |
| Savior Lifetec Corporation | -812.54 Million TWD | 63.083% |
| OBI Pharma, Inc. | -398.22 Million TWD | 24.674% |
| Meribank Biotech Co., Ltd | -365.41 Million TWD | 17.911% |
| Acepodia, Inc. | -6.02 Billion TWD | 95.017% |
| Caliway Biopharmaceuticals Co., Ltd. | -3.4 Billion TWD | 91.182% |